Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average Price Target from Brokerages

Immunic, Inc. (NASDAQ:IMUX) has earned an average rating of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.67.

Several equities research analysts have commented on the company. D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. William Blair assumed coverage on shares of Immunic in a research note on Tuesday, March 25th. They set an “outperform” rating for the company. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th.

Institutional Investors Weigh In On Immunic

A number of large investors have recently added to or reduced their stakes in IMUX. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. HB Wealth Management LLC bought a new position in Immunic in the fourth quarter valued at about $81,000. State Street Corp boosted its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Immunic during the 3rd quarter valued at about $50,000. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of IMUX opened at $1.20 on Friday. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The firm’s 50-day simple moving average is $1.08 and its two-hundred day simple moving average is $1.21. The stock has a market cap of $108.09 million, a PE ratio of -0.98 and a beta of 1.89.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.